Botulinum Toxin

Type A (Botox, onabotulinumtoxinA)Not a peptide · protein toxinGI/Bone/Other

Evidence grade

AFDA-approved Rx (labeled use)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeNeuromuscular

MechanismCleaves SNAP-25 at the presynaptic terminal, blocking acetylcholine release and so neuromuscular transmission at the injected site.

EffectsLocalised, reversible muscle relaxation. Used for spasticity, chronic migraine, overactive bladder, hyperhidrosis and cosmetic indications.

DosingDose is specific to indication and expressed in Units that are NOT interchangeable between botulinum toxin products. The label gives, for example, 100 Units total for overactive bladder across 20 detrusor sites, and 4–8 Units/kg to a maximum of 300 Units for paediatric lower-limb spasticity. Administration is a clinical procedure, not a self-directed one.

Bottom lineAn FDA-approved prescription biologic administered by clinicians, included here for reference rather than as a self-administered compound.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Contraindicated in hypersensitivity to any botulinum toxin preparation and in infection at the injection site. Carries a boxed warning for distant spread of toxin effect. Units are product-specific and confusing them is a dosing error, not a rounding difference.

Co-administration with aminoglycosides or other agents interfering with neuromuscular transmission, such as curare-like compounds, may potentiate the toxin’s effect and should be approached with caution. No formal interaction studies have been conducted.

CV 1 of 5 — No meaningful cardiovascular activity at labelled local doses. Systemic spread is the safety concern, not a cardiovascular one.